Page 272 - Economy & Policy Analysis
PM holds out promise of 8% growth in medium term, but will he deliver?
With growth estimated at 5% for 2012-13 and 6.1-6.7% next year, 8% growth in 12th five year plan sounds optimistic
 "PM holds out promise of 8% growth in medium term, but will he deliver?")
Elusive hunt for skills and jobs
Budget outlays will not do much for job creation or readying youth for skilled work
 "Elusive hunt for skills and jobs")
The man behind Glivec hails verdict
Brian Druker, who invented the drug's molecule, says it would benefit patients in the short term
 "The man behind Glivec hails verdict")
Insight: India Worst 20
Anything which could be reviewed quarterly and more could be considered passive
Patent problems
Novartis judgment might have many side effects
 "No incentive to Indian pharma to innovate")
 "Strictest patent laws will foster genuine innovation")
Half-baked research and lies
Why large pharma companies should not be allowed to charge whatever they like for life-saving drugs
SC verdict on Glivec to impact multinational pharma companies
The apex court verdict on Glivex has wide scale ramifications for multi-nationals operating in India. Meanwhile, the verdict will also benefit Indian generic drug producers and cancer patients in the
 "SC verdict on Glivec to impact multinational pharma companies")
Five reasons why April 1 will be a red-letter day for big pharma
If Novartis wins the case for patenting Glivec, it could result in the end of affordable medicines for substantially large section of the Indian population
 "Five reasons why April 1 will be a red-letter day for big pharma")
Will India keep Novartis at bay?
Wants to patent cancer drug, Glivec, in India
 "Will India keep Novartis at bay?")
Big Pharma in nervous wait for verdict on Glivec patent
If Novartis' cancer drug is denied IPR, it will be the latest in a string of causalties faced by global players such as Bayer, Pfizer and Roche
 "Big Pharma in nervous wait for verdict on Glivec patent")
 "As Novartis judgement day looms, Big Pharma bites its nails")
StatsGuru-1-April-2013
The story for stocks in 2012-13
 "Drought of equity")
Doing less with more: India's health care system
Much of the health care spending in India, and in the rest of the world, is on expensive and ineffective forms of treatment
 "Doing less with more: India's health care system")
Next port of call
Industrialisation has changed the lives of the genteel folk of Tuticorin in Tamil Nadu. With the port town ready for more action, a bigger transformation awaits